How did Kenvue (NYSE:KVUE) perform in Q1 2026?

Kenvue reported Q1 2026 net sales of $3.89 billion, a 4.5% increase year-over-year. This growth was driven by a 3.8% benefit from foreign currency fluctuations, with organic sales growing 0.7%. The company showed strong operational efficiency, with an expanded adjusted gross profit margin of 60.8%. Operating income margin rose to 19.6%, and adjusted operating income margin increased to 24.0%, reflecting successful cost structure improvements.

What contributed to Kenvue’s revenue growth in Q1 2026?

Kenvue's 4.5% revenue growth in Q1 2026 was primarily driven by a 3.8% benefit from favorable foreign currency fluctuations. Organic sales growth was modest at 0.7%, but the company's improved operational efficiency helped sustain overall growth. The performance demonstrates Kenvue’s ability to manage external factors while focusing on internal efficiencies.

How did Kenvue manage its profitability in Q1 2026?

Kenvue's profitability saw a significant boost in Q1 2026. The company's adjusted gross profit margin expanded to 60.8%, up from 60% in the prior year. Operating income margin increased to 19.6%, while adjusted operating income margin rose to 24.0%, reflecting a 420-basis-point improvement. These improvements were largely driven by cost structure optimizations and supply chain efficiencies following its separation from Johnson & Johnson.

What was Kenvue's earnings performance in Q1 2026?

Kenvue reported a 33% increase in adjusted diluted EPS, which rose to $0.32, surpassing the $0.24 reported in Q1 2025. Diluted EPS also increased to $0.25, compared to $0.17 in the prior year. This strong earnings growth reflects the company’s effective cost control and margin expansion during the quarter.

How is Kenvue evolving strategically in 2026?

Kenvue is undergoing a significant strategic evolution, marked by a major transaction involving Kimberly-Clark. This move is expected to further refine Kenvue’s brand portfolio and geographic footprint. As a result of the pending transaction, Kenvue management has decided to withhold forward-looking guidance for the remainder of fiscal 2026, suggesting caution as the deal progresses.

Kenvue profitability rallies in Q1 as margins expand ahead of strategic deal

Written by Heidi Cuthbert Published May. 7 2026Last Updated May. 7 2026

Kenvue (NYSE:KVUE) reported a strong start to the 2026 fiscal year, characterized by significant bottom-line growth and a marked improvement in operational efficiency.

For the fiscal first quarter ended March 29, 2026, the world’s largest pure-play consumer health company by revenue posted net sales of $3.89 billion, a 4.5% increase compared to the prior-year period.

The sales growth was primarily driven by a 3.8% benefit from foreign currency fluctuations, while organic sales grew by a modest 0.7%.

Despite the lean organic growth, Kenvue demonstrated high levels of internal efficiency, with adjusted gross profit margin expanding to 60.8%, up from 60% a year ago.

This margin improvement was fueled by favorable value realization and supply chain optimizations.

Kenvue’s profitability metrics saw a sharp upward trajectory during the quarter.

Operating income margin rose to 19.6% from 14.9%, while adjusted operating income margin expanded significantly to 24.0% from 19.8%.

This 420-basis-point expansion reflects the company's successful efforts to streamline its cost structure following its separation from Johnson & Johnson.

The margin strength translated into robust earnings growth.

While diluted EPS increased to $0.25 compared to $0.17 in the prior-year period, adjusted diluted EPS rose 33% to $0.32, surpassing the $0.24 reported in the first quarter of 2025.

A major focal point for the quarter remains the company's strategic evolution.

Kenvue is currently in the midst of a significant transaction involving Kimberly-Clark, a move expected to further refine its brand portfolio and geographic footprint.

Citing the pending nature of this transaction, Kenvue management took the atypical step of withholding forward-looking guidance for the remainder of the 2026 fiscal year.